journal article·2023-08-02Open access

Recent Advances in Curcumin-Based Combination Nanomedicines for Cancer Therapy

Amir R. Afshari, Mehdi Sanati, Prashant Kesharwani, Amirhossein Sahebkar

Abstract

Standard cancer chemotherapeutics often produce significant adverse effects and eventually lose their effectiveness due to the emergence of resistance mechanisms. As a result, patients with malignant tumors experience a poor quality of life and a short lifespan. Thus, combination medication regimens provide various advantages, including increased success rate, fewer side effects, and fewer occurrences of resistance. Curcumin (Cur), a potential phytochemical from turmeric, when coupled with traditional chemotherapeutics, has been established to improve the effectiveness of cancer treatment in clinical and preclinical investigations. Cur not only exerts multiple mechanisms resulting in apoptotic cancer cell death but also reduces the resistance to standard chemotherapy drugs, mainly through downregulating the multi-drug resistance (MDR) cargoes. Recent reports showed the beneficial outcomes of Cur combination with many chemotherapeutics in various malignancies. Nevertheless, owing to the limited bioavailability, devising co-delivery strategies for Cur and conventional pharmaceuticals appears to be required for clinical settings. This review summarized various Cur combinations with standard treatments as cancer therapeutics.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Curcumin's Biomedical Applications · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Physiology and Pharmacology, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran

Experimental and Animal Study Center, Birjand University of Medical Sciences, Birjand, Iran

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India

Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 602105, India

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

References (100+)

Show source-provided references
1. Combination therapy in combating cancer10.18632/oncotarget.16723 ↗
2. Shimamura, S.S., Shukuya, T., Asao, T., Hayakawa, D., Kurokawa, K., Xu, S., Miura, K., Mitsuishi, Y., Tajima, K., and Shibayama, R. (2022). Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—Is there a “tail plateau” in the survival curve of these patients?. BMC Cancer, 22.10.1186/s12885-022-09421-7 ↗
3. Historical perspective on surgery and survival with glioblastoma: How far have we come?10.1016/j.wneu.2021.02.047 ↗
4. Change in survival in metastatic breast cancer with treatment advances: Meta-analysis and systematic review10.1093/jncics/pky062 ↗
5. Current challenges in cancer treatment10.1016/j.clinthera.2016.03.026 ↗
6. Khatoon, E., Banik, K., Harsha, C., Sailo, B.L., Thakur, K.K., Khwairakpam, A.D., Vikkurthi, R., Devi, T.B., Gupta, S.C., and Kunnumakkara, A.B. (2020). Seminars in Cancer Biology, Elsevier.
7. Sanati, M., Afshari, A.R., Ahmadi, S.S., Moallem, S.A., and Sahebkar, A. (BioFactors, 2023). Modulation of the ubiquitin-proteasome system by phytochemicals: Therapeutic implications in malignancies with an emphasis on brain tumors, BioFactors, early view.10.1002/biof.1958 ↗
8. Targeting angiogenesis in gliomas: Potential role of phytochemicals10.1016/j.jff.2022.105192 ↗
9. Curcumin: An inflammasome silencer10.1016/j.phrs.2020.104921 ↗
10. Curcumin supplementation in pediatric patients: A systematic review of current clinical evidence10.1002/ptr.7350 ↗
11. Curcumin, hemostasis, thrombosis, and coagulation10.1002/jcp.26249 ↗
12. Protective effects of curcumin against traumatic brain injury10.1016/j.biopha.2022.113621 ↗
13. The protective role of curcumin in myocardial ischemia–reperfusion injury
14. Difluorinated curcumin: A promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile10.2174/1381612822666160527113501 ↗
15. Curcumin: A natural modulator of immune cells in systemic lupus erythematosus10.1016/j.autrev.2017.11.016 ↗
16. Molecular mechanisms for curcumin benefits against ischemic injury10.1016/j.fertnstert.2010.07.1071 ↗
17. Phytosomal curcumin inhibits tumor growth in colitis-associated colorectal cancer10.1002/jcp.26538 ↗
18. Curcumin in combined cancer therapy10.2174/1381612820666140826154601 ↗
19. Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review10.1016/j.critrevonc.2017.12.005 ↗
20. Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?10.1021/acsomega.2c07326 ↗
21. The golden spice curcumin in cancer: A perspective on finalized clinical trials during the last 10 years10.4103/jcrt.JCRT_1017_20 ↗
22. Curcumin in combination with anti-cancer drugs: A nanomedicine review10.1016/j.phrs.2018.11.005 ↗
23. Nanomedicine and chemotherapeutics drug delivery: Challenges and opportunities10.1080/1061186X.2020.1808000 ↗
24. Diagnosis and treatment of metastatic colorectal cancer: A review10.1001/jama.2021.0106 ↗
25. Shakibaei, M., Buhrmann, C., Kraehe, P., Shayan, P., Lueders, C., and Goel, A. (2014). Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures. PLoS ONE, 9.10.1371/journal.pone.0085397 ↗
26. Shakibaei, M., Mobasheri, A., Lueders, C., Busch, F., Shayan, P., and Goel, A. (2013). Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathways. PLoS ONE, 8.10.1371/journal.pone.0057218 ↗
27. Shakibaei, M., Kraehe, P., Popper, B., Shayan, P., Goel, A., and Buhrmann, C. (2015). Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. BMC Cancer, 15.10.1186/s12885-015-1291-0 ↗
28. Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice10.1186/s13046-017-0661-7 ↗
29. Curcumin analog pentagamavunon-1 (PGV-1) sensitizes Widr cells to 5-fluorouracil through inhibition of NF-κB activation
30. Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo10.6061/clinics/2013(05)18 ↗
31. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer10.1093/carcin/bgv006 ↗
32. Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress10.1016/j.biopha.2020.110381 ↗
33. Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway10.2147/OTT.S199601 ↗
34. Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment10.1016/j.bbagen.2014.06.004 ↗
35. In vitro combinatorial anticancer effects of 5-fluorouracil and curcumin loaded N, O-carboxymethyl chitosan nanoparticles toward colon cancer and in vivo pharmacokinetic studies10.1016/j.ejpb.2014.04.017 ↗
36. Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells10.1016/j.pharep.2017.10.004 ↗
37. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX10.1593/tlo.09193 ↗
38. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R
39. Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy10.1016/j.canlet.2015.05.005 ↗
40. Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial10.1093/jn/nxz029 ↗
41. Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil10.1038/cddis.2013.26 ↗
42. Self-assembled silk fibroin nanoparticles loaded with binary drugs in the treatment of breast carcinoma10.2147/IJN.S108633 ↗
43. Curcumin and paclitaxel induce cell death in breast cancer cell lines
44. GANT61 and curcumin-loaded PLGA nanoparticles for GLI1 and PI3K/Akt-mediated inhibition in breast adenocarcinoma10.1088/1361-6528/ab6d20 ↗
45. Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: In vitro and in vivo evaluation10.1016/j.colsurfb.2019.110515 ↗
46. Co-delivery of doxorubicin and curcumin to breast cancer cells by a targeted delivery system based on Ni/Ta core-shell metal-organic framework coated with folic acid-activated chitosan nanoparticles10.1007/s13738-022-02604-w ↗
47. Recent advances in prostate cancer treatment and drug discovery10.3390/ijms19051359 ↗
48. Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer
49. The new combination docetaxel, prednisone and curcumin in patients with castration-resistant prostate cancer: A pilot phase II study10.1159/000441148 ↗
50. Curcumin Upregulates miR-148a to Increase the Chemosensitivity of CD44-Positive Prostate Cancer Stem Cells to Paclitaxel Through Targeting the MSK1/IRS1 axis10.1055/a-1867-4805 ↗
51. Combination of curcumin and metformin inhibits cell growth and induces apoptosis without affecting the cell cycle in LNCaP prostate cancer cell line10.1080/01635581.2020.1783327 ↗
52. Anti prostate cancer therapy: Aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles10.1016/j.biopha.2020.110181 ↗
53. Curcumin potentiates the antitumor activity of Paclitaxel in rat glioma C6 cells10.1016/j.phymed.2018.08.009 ↗
54. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in inducing gastric cancer cell apoptosis both in vitro and in vivo10.3727/096504015X14452563486011 ↗
55. Curcumin enhances the anticancer effect of 5-fluorouracil against gastric cancer through down-regulation of COX-2 and NF-κB signaling pathways10.7150/jca.20196 ↗
56. Curcumin reverses doxorubicin resistance via inhibition the efflux function of ABCB4 in doxorubicin-resistant breast cancer cells
57. Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression10.18632/oncotarget.24109 ↗
58. Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells
59. Enhanced anticancer potency of doxorubicin in combination with curcumin in gastric adenocarcinoma10.1002/jbt.22486 ↗
60. Combined effects of curcumin and doxorubicin on cell death and cell migration of SH-SY5Y human neuroblastoma cells10.1007/s11626-018-0288-9 ↗
61. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death10.1186/s13046-019-1234-8 ↗
62. Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop10.1016/j.phymed.2018.04.058 ↗
63. Curcumin enhances cisplatin-induced human laryngeal squamous cancer cell death through activation of TRPM2 channel and mitochondrial oxidative stress10.1038/s41598-019-54284-x ↗
64. The modulation study of multiple drug resistance in bladder cancer by curcumin and resveratrol
65. Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin-resistant oral cancer CAR cells through intrinsic apoptotic process
66. Synergistic antiproliferative effects of curcumin and celecoxib in hepatocellular carcinoma HepG2 cells10.1007/s00210-018-1557-6 ↗
67. mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy10.1038/s41388-018-0345-6 ↗
68. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers10.1016/j.colsurfb.2018.03.046 ↗
69. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma10.1016/j.ijpharm.2018.05.007 ↗
70. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine10.1016/j.biopha.2019.108614 ↗
71. Co-delivery of doxorubicin and curcumin with polypeptide nanocarrier for synergistic lymphoma therapy10.1038/s41598-020-64828-1 ↗
72. Multidrug resistance affects the prognosis of primary epithelial ovarian cancer
73. Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update10.1016/j.ejmech.2022.114542 ↗
74. Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells10.3892/ol.2016.5192 ↗
75. Co-delivery of curcumin and paclitaxel by “core-shell” targeting amphiphilic copolymer to reverse resistance in the treatment of ovarian cancer10.2147/IJN.S224579 ↗
76. Duse, L., Agel, M.R., Pinnapireddy, S.R., Schäfer, J., Selo, M.A., Ehrhardt, C., and Bakowsky, U. (2019). Photodynamic therapy of ovarian carcinoma cells with curcumin-loaded biodegradable polymeric nanoparticles. Pharmaceutics, 11.10.3390/pharmaceutics11060282 ↗
77. Curcumin-loaded PEGylated mesoporous silica nanoparticles for effective photodynamic therapy10.1039/D0RA04778C ↗
78. PEGylated lipid nanocarrier for enhancing photodynamic therapy of skin carcinoma using curcumin: In-vitro/in-vivo studies and histopathological examination10.1038/s41598-020-67349-z ↗
79. Emerging nanotherapeutics for facilitating photodynamic therapy10.1016/j.cej.2022.138621 ↗
80. Self-delivered and self-monitored chemo-photodynamic nanoparticles with light-triggered synergistic antitumor therapies by downregulation of HIF-1α and depletion of GSH10.1021/acsami.9b23325 ↗
81. Busa, P., Kankala, R.K., Deng, J.-P., Liu, C.-L., and Lee, C.-H. (2022). Conquering cancer multi-drug resistance using curcumin and cisplatin prodrug-encapsulated mesoporous silica nanoparticles for synergistic chemo-and photodynamic therapies. Nanomaterials, 12.10.3390/nano12203693 ↗
82. Two-dimensional nanosheets with high curcumin loading content for multimodal imaging-guided combined chemo-photothermal therapy10.1016/j.biomaterials.2019.119470 ↗
83. Gadolinium-doped hollow silica nanospheres loaded with curcumin for magnetic resonance imaging-guided synergistic cancer sonodynamic-chemotherapy10.1016/j.msec.2021.112157 ↗
84. Multiplex fluorescence imaging-guided programmed delivery of doxorubicin and curcumin from a nanoparticles/hydrogel system for synergistic chemotherapy10.1002/pol.20210600 ↗
85. The power of phytochemicals combination in cancer chemoprevention10.7150/jca.34374 ↗
86. Combination of phytochemicals as adjuvants for cancer therapy10.2174/1574892809666140619154838 ↗
87. Nanotechnology for the delivery of phytochemicals in cancer therapy10.1016/j.biotechadv.2016.04.002 ↗
88. Mukherjee, S., Baidoo, J.N., Sampat, S., Mancuso, A., David, L., Cohen, L.S., Zhou, S., and Banerjee, P. (2018). Liposomal TriCurin, a synergistic combination of curcumin, epicatechin gallate and resveratrol, repolarizes tumor-associated microglia/macrophages, and eliminates glioblastoma (GBM) and GBM stem cells. Molecules, 23.10.3390/molecules23010201 ↗
89. Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids10.1080/01635580802416703 ↗
90. A combination of curcumin and oligomeric proanthocyanidins offer superior anti-tumorigenic properties in colorectal cancer10.1038/s41598-018-32267-8 ↗
91. Curcumin-and piperine-loaded emulsomes as combinational treatment approach enhance the anticancer activity of curcumin on HCT116 colorectal cancer model10.3389/fbioe.2020.00050 ↗
92. Pro-apoptotic genes as new targets for single and combinatorial treatments with resveratrol and curcumin in colorectal cancer10.1039/C9FO01014A ↗
93. Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines10.1002/jcp.27761 ↗
94. Curcumin and Thymoquinone Combination Attenuates Breast Cancer Cell Lines’ Progression10.1177/15347354221099537 ↗
95. Gallic acid and curcumin induce cytotoxicity and apoptosis in human breast cancer cell MDA-MB-23110.15171/bi.2018.21 ↗
96. Efficient synergistic combination effect of Quercetin with Curcumin on breast cancer cell apoptosis through their loading into Apo ferritin cavity10.1016/j.colsurfb.2020.110982 ↗
97. Synergistic antiproliferative effects of co-nanoencapsulated curcumin and chrysin on mda-mb-231 breast cancer cells through upregulating mir-132 and mir-502c10.1080/01635581.2019.1599968 ↗
98. Curcumin and quercetin synergistically inhibit cancer cell proliferation in multiple cancer cells and modulate Wnt/β-catenin signaling and apoptotic pathways in A375 cells10.1016/j.phymed.2018.09.224 ↗
99. Synergistic induction of apoptosis by quercetin and curcumin in chronic myeloid leukemia (K562) cells10.1080/01635581.2018.1380208 ↗
100. Curcumin and resveratrol inhibit chemoresistance in cisplatin-resistant epithelial ovarian cancer cells via targeting P13K pathway10.1177/09603271221095929 ↗